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Abstract
Background: Personalised treatment that is uniquely tailored to an individual’s phenotype has become a key goal
of clinical and pharmaceutical development across many, particularly chronic, diseases. For type 2 diabetes, the
importance of the underlying clinical heterogeneity of the condition is emphasised and a range of treatments are
now available, with personalised approaches being developed. While a close connection between risk factors for
type 2 diabetes and gestational diabetes has long been acknowledged, stratification of screening, treatment and
obstetric intervention remains in its infancy.
Conclusions: Although there have been major advances in our understanding of glucose tolerance in pregnancy
and of the benefits of treatment of gestational diabetes, we argue that far more vigorous approaches are needed
to enable development of companion diagnostics, and to ensure the efficacious and safe use of novel therapeutic
agents and strategies to improve outcomes in this common condition.
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Background
May 2018 will mark 10 years since the publication of the
seminal Hyperglycemia and Adverse Pregnancy Outcomes
Study (HAPO) [1] and 8 years since new criteria and
pathway for diagnosis of gestational diabetes (GDM) were
proposed by the International Association of Diabetes and
Pregnancy Study Groups (IADPSG) [2]. Landmark studies
of the treatment of 'mild' GDM had been published before
this in 2005 [3] and 2009 [4]. The IADPSG criteria have
been largely adopted by several national and international
societies, notably by the World Health Organisation
(WHO) [5] and International Federation of Gynecology
and Obstetrics (FIGO) [6], but others, most influentially
the American College of Obstetricians and Gynecologists
(ACOG) [7] and the National Institute for Health and
Care Excellence (NICE) [8] have not adopted the criteria.
Although much has been achieved, it is perhaps disap-
pointing that the goal of a more unified pattern of screen-
ing and diagnosis has not been realized. This is especially
true given that there is now overwhelming evidence that
there is a graded linear association between either fasting
or post-load glucose concentrations and both fetal growth
and important adverse perinatal outcomes [9].
The lack of an inflection point at which risk increases
means that decisions regarding diagnostic thresholds may
be reasonably disputed, but setting some threshold for
clinical decision-making is unavoidable. Critically, how-
ever, those thresholds should be set on the basis of defined
clinical risks and benefits, with clear-sighted agreement as
to whether these apply to perinatal and longer-term out-
comes. In turn, it would appear that the use of individual
data and calculated risk would be the most effective way
in which to apply such a threshold.
By whichever criterion we diagnose GDM, its impact
and that of associated metabolic disorders, such as type 2
diabetes mellitus (T2DM), in pregnancy grows ever more
concerning. Rates of T2DM and obesity in pregnancy con-
tinue to increase. As the HAPO trial made clear, maternal
glucose is one risk factor that predicts a continuum of
risk, but additional risk factors such as body mass index
(BMI) can also have an independent effect [1, 10]. Here,
we review some recent developments in the prevention,
screening, diagnosis and treatment of GDM and argue
that efforts to individualise these processes should be cen-
tral to the next ten years of development in this area.
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Preventing gestational diabetes: right person,
right treatment?
GDM is associated with a number of well-described
risk factors. The past few years have been notable for a
number of excellently conducted trials that have
attempted to determine whether intervention with ex-
ercise, diet or lifestyle, or pharmaceutical intervention
with metformin, might reduce the incidence of GDM in
pregnancy. These are potentially attractive options, not
least as the concept of lifestyle modification, for example
smoking cessation, during pregnancy is well accepted.
Exercise has a number of known benefits in pregnancy
and is already recommended [11]. Unfortunately, it has
been surprisingly difficult to find an effective intervention
to reduce the risk of GDM.
In the two largest lifestyle intervention trials to date,
LIMIT (n = 2152 overweight and obese women) and UP-
BEAT (n = 1555 obese women), exercise and dietary
change did not reduce either GDM or rates of large for
gestational age babies [12]. More generally, while diet or
exercise or their combination may reduce gestational
weight gain modestly [13], it is far from clear that this re-
duction translates into a reduction in GDM when applied
to more general populations [14, 15]. This has been seen
most recently in the DALI (vitamin D and lifestyle inter-
vention) trial of diet and physical activity, during which a
combination of these interventions was successful in
limiting gestational weight gain but did not alter fasting
glycaemia in women at risk of GDM [16]. Similarly, the
two large intervention trials administering metformin in
pregnancy in obese women (N = 449 and N = 450) have
failed to show any reduction in the incidence of GDM
[17, 18]. There are some trials suggesting a positive ef-
fect of lifestyle intervention on GDM prevention. In the
ROLO trial (N = 800 women with previous large for
gestational age babies), a low glycaemic index diet was
associated with a reduction in maternal glucose intoler-
ance [19]. In the RADIEL trial (n = 293 women with a
history of GDM and/or obesity), incidence of GDM was
reduced by 39% with lifestyle intervention [20]. Notably,
for the negative trials, inclusion was primarily predicated
on BMI, rather than on a more sophisticated stratification
of risk. For ROLO, secondary analysis identified that those
women who were more likely to respond to the interven-
tion had a slightly lower BMI, greater insulin resistance in
early pregnancy, and lower circulating leptin at baseline
[21]. RADIEL included a relatively high proportion of
women with GDM in a previous pregnancy (30–35%
[20]), which raises the possibility that differences in the
underlying patterns of risk factors might underpin the dis-
cordance in results despite the similarity in intervention.
It is also possible that particular types of diet, most
notably a Mediterranean diet, may be helpful but data are
largely limited to observational series [22].
The concept that T2DM is a heterogeneous condition,
with multiple phenotypes and pathological pathways at-
tached to a common disease label, is now a very familiar
one [23]. Despite the strong association between GDM
and future risk of T2DM, there has been less consider-
ation of the possibility that GDM may also reflect a
relative umbrella term with multiple threads. That the het-
erogeneous pathophysiologies of these two conditions
may also differ has not been widely considered. The con-
cept that T2DM is preceded by increases in liver and beta
cell fat content (triacylglycerol), and that this can be re-
versed by weight loss, has become influential recently
[24]. By contrast, GDM does not appear to be associated
with an increase in liver triacylglycerol [25]. Furthermore,
in a small study of 14 women with GDM, calorie restric-
tion over a 4-week period reduced liver triacylglycerol
from what were apparently already normal levels, but this
reduction was still associated with a reduced need for
pharmacological therapy as compared to matched con-
trols [25]. Taken together, these findings may suggest, first,
that there are differences in pathophysiology, perhaps
explaining why lifestyle and pharmacological interventions
have had inconsistent effects in comparison to similar
interventions to prevent T2DM. Second, the evidence
suggests that we need to understand the heterogeneity of
GDM risk in individuals in order to facilitate the targeting
of preventative strategies.
Screening and diagnosis: right person, right time?
There has been extensive debate on which screening
and diagnostic criteria are most appropriate. That de-
bate has been extensively aired elsewhere [26] and the
risk characteristics of patients diagnosed under one or
other system examined [27]. It can be noted that rec-
ommendations still vary as to whether all women or
only women with risk factors (usually including a meas-
ure of obesity or overweight, previous macrosomia, ethni-
city, and/or family history of diabetes or polycystic ovary
syndrome [PCOS]) are screened biochemically [2, 5, 6].
Inevitably, any pre-selection that is based on any single
risk factor, which has in itself only a modest association
with GDM, will perform relatively poorly. So although
stratification of screening to identify those at greatest risk
may seem attractive, the efficacy of this approach will be
limited and universal screening is more efficacious in pop-
ulations with a high prevalence of any individual risk
factor. An alternative approach is to try to develop more
accurate multivariate models to identify those at risk,
particularly as early pregnancy models would also enable
early targeted intervention [28]. Although multiple bio-
markers that have been associated with T2DM have been
examined, circulating metabolic measures such as assess-
ment of adiponectin levels appear to be most promising
[29]. Evaluation of a novel early pregnancy screening
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algorithm and an intervention could be undertaken simul-
taneously [30].
An alternative approach is to shift the timing of the
diagnostic test that confirms GDM. Traditionally, screen-
ing and diagnostic thresholds are applicable at 24 to
28 weeks. This makes some sense in terms of the dynam-
ics of change of glucose in pregnancy, but limits the
period during which intervention can occur. More subtle
metabolic perturbations can be identified prior to the
diagnosis of GDM or early in pregnancy in obese women,
and what is more striking is that these changes have a bio-
logical consequence. The POP study showed that fetal
growth is increased even at the time of diagnosis of GDM
at 28 weeks, an increase that is not apparent at 20 weeks
[31]. This adds weight to the logic of questioning the
timing of current GDM diagnosis and suggests that an
opportunity for intervention might be being missed. Even
more strikingly, growth is already increased in the fetuses
of obese women by 20 weeks gestation, suggesting that
successful interventions might need to occur even earlier
in this group if growth is to become normal [31].
As an additional issue, although the original IADPSG
report suggested that the new criteria could also be
used in screening in early pregnancy [2], this approach
has been controversial. There is an undoubted clinical
need to find women with undiagnosed diabetes in early
pregnancy, especially in populations with high preva-
lence of undiagnosed T2DM. Nevertheless, the most
clinically relevant and cost effective way of doing this is
not clear at present. A separate aim is to identify
women who might benefit from early intervention to
prevent GDM. This could be achieved relatively easily
as a research study. Testing both during early preg-
nancy and again at 24–28 weeks, with the identification
of appropriate first-trimester values that are sufficiently
sensitive and specific to allow them to replace agreed
IADPSG or alternative thresholds at 24–28 weeks,
would enable the field to move forward. Alternative
novel biomarkers that could replace the dynamic oral
glucose tolerance test could then be validated on the
same large cohort and associated biobank.
Treating gestational diabetes: right treatment?
The cornerstone of treatment of GDM remains dietary
intervention. Other positive lifestyle changes including
increased exercise are also encouraged. Lifestyle modifi-
cation is a critical component of GDM treatment, and
it should be remembered that the successful treatment
trials of 'mild' GDM involved treatment protocols that
relied on dietary therapy alone in over 80% of cases [3, 4].
The nutrition recommendations of the American Diabetes
Association (ADA) were followed [4]. After the year 2000,
treatment underwent a major change in many countries
with the trials of glyburide (also known as glibenclamide)
[32] and metformin [33], allowing use of these agents
usually prior to insulin therapy. Treatment selection is
relatively unsophisticated: most patients will begin with
diet, then proceed to an oral hypoglycaemic and finally
progress to insulin treatment. That insulin is frequently
required even with use of oral hypoglycaemics suggests ei-
ther that the glycaemic challenge of pregnancy is too great
for the oral hypoglycaemics used at present or that
there is a potential mismatching of the optimal oral
therapy with the patient profile [32, 33]. The unique
safety concerns associated with potential transplacental
transfer and effects on the fetus have limited the evalu-
ation of efficacious pharmacological treatments such as
dipeptidyl peptidase-4 inhibitors, sodium–glucose cotran-
sporter 2 inhibitors or GLP-1 mimetics, which are rou-
tinely used for T2DM. This limitation is likely to continue.
As for the use of other non-licensed medications during
pregnancy, unplanned exposure in early pregnancy will
allow only some, imperfect assessment of safety. The po-
tential weight loss associated with some of these agents
should also limit use in pregnancy and mandates only
careful trials for their evaluation. It would seem likely,
however, that pharmaceutical companies will be reluctant
to take on the expense and possible risk of such trials.
Can we select which women are best suited for one or
other of the currently available oral therapies? The evi-
dence base is small and so outcomes in subgroups have
not been reported extensively. When considering glucose-
lowering effects, the existing randomized control trial and
observational series suggest that the failure of glibencla-
mide is more likely when initial fasting glucose is high
(above 6.4 mmol/l) [34]. These observations make sense
as women with higher glucose levels are likely to have
more severe disease. Similarly, in observations of met-
formin use, women who required supplemental insulin
had higher BMI in early pregnancy than those main-
tained on metformin (33.6 ± 8.6 kg/m2 vs 31.1 ± 7.8 kg/
m2 ); likewise, baseline glucose levels were higher in
those requiring supplemental insulin (6.1 ± 1.1 mmol/l)
than in those not requiring supplemental insulin (5.3 ±
0.8 mmol/l) [33]. Metformin does have an advantage in
being associated with less weight gain than either insu-
lin or glibenclamide, and it may be more attractive in
general for this reason [33]. In the future, pharmaco-
genetics might help with this selection, but large studies
will be needed and evidence of robust effects for met-
formin is currently lacking, even in type 2 diabetes [35].
More broadly, several studies have attempted to predict
which women might need insulin therapy for GDM. A
range of factors—maternal age, family history of diabetes,
obesity, prior GDM, early diagnosis of GDM, higher fast-
ing venous blood glucose level and HbA1c—have been
shown to be predictive and may be useful to guide inten-
sity of follow-up [36].
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The relative benefits of the various agents used to re-
duce complications, such as pre-eclampsia, are less clear.
Pre-eclampsia risk in GDM is 1.5-fold greater than that
of the background population [37] and treatment of
'mild' GDM reduces risk of preeclampsia by 30–32%
[3, 4], a greater benefit than that provided by other
preventative strategies such as low-dose aspirin (which
provides a more modest 10% risk reduction in high-
risk pregnancy) [38]. Meta-analyses have suggested
additional benefit with metformin therapy compared
with insulin or glibenclamide treatments in preventing
pregnancy-induced hypertension [39, 40], but this is
only a non-significant trend towards lower pre-eclampsia
rates seen in studies that are underpowered in their ability
to test this association. Examination of whether such
benefits can be extended to other patient groups remains
at an early stage [17, 18]. In general, the mechanisms of
how reduced glucose levels alter preeclampsia risk,
whether this mechanism differs between agents and, in
turn, whether this should influence therapeutic choices
and patient selection remain understudied issues.
A further contentious area has been the risk of neonatal
hypoglycemia with glibenclamide use. While initial studies
suggested that glibenclamide does not cross the placenta
at significant levels [41], studies have now shown that it
does cross the placenta but is then actively effluxed out of
the fetal unit by a specific transporter (placental breast
cancer resistance protein) [42]. Polymorphism in this pro-
tein can lead to variable levels of glibenclamide in the
fetus [42]. This, along with the observation that neonatal
outcomes may be inferior with glibenclamide, particularly
for neonatal hypoglycemia [34, 39], has led bodies such as
the ADA to recommend insulin as the first-line agent after
diet [43]. The ADA also notes the lack of long-term safety
data for either metformin or glibenclamide in that recom-
mendation [43]. Both agents cross the placenta and so
there is potential for long-term programming effects, ei-
ther directly by the drug or, in the case of glibenclamide,
by induction of fetal hyperinsulinaemia. Metformin is
known to increase adenosine monophosphate-activated
protein kinase (AMPK) and increases in AMPK may be
important in utero-; for example, they are important in
diabetic embryopathy [44]. Importantly, animal studies
have not suggested an increase in embryopathy with early
metformin exposure in vivo [44], and meta-analyses of hu-
man studies based on metformin exposure in women with
PCOS also do not suggest any increase in congenital
anomalies [45]. Nevertheless, there could be a question as
to whether metformin exposure will have longer-term
effects.
Randomized evidence arising from exposure during
pregnancy extends only to 2 years, but is largely reassur-
ing. In data from the MIG study (MIG TOFU), children
exposed to metformin in utero had normal total fat mass
and percentage body fat as assessed by bioimpedance, al-
though these children did have slightly larger mid-upper
arm circumferences and subscapular and biceps skin-
folds [46]. There were no differences in blood pressure
[47]. Follow-up of a Finnish randomized controlled trial
(RCT) found that children who were exposed to metfor-
min in pregnancy were significantly heavier at the age of
12 months, and both taller and heavier (12.0 vs 11.3 kg)
at 18 months. The mean ponderal index did not differ
significantly. Motor, social and linguistic development
evaluated at the age of 18 months did not differ between
the groups [48]. A recent review noted the limitations of
the size of the study and the length of follow-up in the
available studies [40]. Different clinicians are likely to in-
terpret this evidence base differently when recommend-
ing glibenclamide, metformin or insulin to their patients.
Overall, it is important to note that, in recent years, we
have been fortunate to have detailed RCTs examining
different agents in pregnancy. Given the heterogeneity of
T2DM and GDM, it would be useful to have a wider
range of therapies. At present, the pharmacological re-
sources available appear to be becoming more rather
than less limited, as glibenclamide use declines.
Finally, there is limited information comparing different
treatment targets, independent of which treatment is used
to lower glucose, particularly for type 1 and type 2 dia-
betes. In GDM, the interventional trials [3, 4] followed set
algorithms for escalation of treatment (for example, treat-
ment escalated when fasting glucose exceeded 5.5 mmol/l
or when glucose values two hours after meals exceeded
7.0 mmol/l) but few studies have compared different
targets. The study of de Veciana et al. [49] supported
the importance of using post-prandial rather than pre-
prandial targets for insulin adjustment in GDM using a
randomised design leading to the wider adoption of
post-prandial monitoring.
Obstetric decision making: right monitoring and
timing of delivery?
With the potential tsunami of GDM, antenatal care path-
ways that classically stratify GDM into a high-risk care
pathway need to be reconsidered. Routine antenatal visits
primarily focus on detecting hypertensive disorders of
pregnancy and abnormalities of fetal growth, which are
substantially less prevalent than GDM. An alternative
model that enables GDM-affected women who only re-
ceive lifestyle modification or oral agents to continue in
their respective non-specialist services can be attainable
with appropriate education of healthcare providers. The
cost of instruction, of the consumables used for frequent
self-monitored blood glucose (SMBG) assessments and of
more intensive antenatal care are the greatest costs of
antenatal GDM provision. These costs potentially nullify
the cost-effectiveness of GDM screening and treatment,
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suggesting that alternative more sophisticated approaches
are required. The purpose of the SMBG is to identify
those that will benefit from intensification of therapy, but
it also facilitates learning and reinforcement of the import-
ance of an optimal diet. Validated treatment escalation al-
gorithms (indicating glucose levels at which treatment is
increased) [3, 4] and remote management of SMBG moni-
tors (which can be used with the smart devices that are
routinely carried by patients of this age-group) may facili-
tate a reduction in patient inconvenience and the need for
widespread attendance at specialist services.
The second greatest contribution to the antenatal costs
of GDM management is the inclusion of additional ultra-
sounds for fetal growth. Long-standing opinions regarding
the lack of merit of routine ultrasound for fetal growth
from 24 weeks onwards are now being challenged [50].
Data from blinded ultrasound measurements, performed
at 28 weeks and 36 weeks in nulliparous women, show
that the identification of fetuses with an estimated fetal
weight of less than the 10th percentile and an abdominal
circumference growth velocity in the lowest decile can
identify those small for gestational age fetuses at increased
risk of neonatal morbidity [51]. Adoption of these two
scans into current routine care would, first, enable identi-
fication of GDM-affected fetuses with abnormal growth at
the time of diagnosis and ensure early intensification of
treatment. Second, the identification at 36 weeks of fetuses
that have impaired growth due to placental dysfunction
later in pregnancy and would identify those that would
benefit from expedited delivery, while balancing against
widespread iatrogenic premature delivery. Conversely,
for those fetuses with an anticipated estimated fetal
weight above the 95th centile, induction of labor at 37
to 38 + 6 weeks is associated with a reduced risk of
shoulder dystocia and associated morbidity as com-
pared to expectant management [52]. The value of hav-
ing an additional third scan at 32 weeks may be limited
in this context because SMBG monitoring rather than
ultrasound indices would primarily indicate the need
for treatment escalation. Similarly, detection of abnormal
growth to the extent that would precipitate premature de-
livery is unlikely in the absence of alteration of SMBG
monitoring or other clinical signs. In many healthcare sys-
tems, routine ultrasound at all three time points is already
provided, in which case there is essentially no increase in
the ultrasonographic cost of GDM.
Conclusions
We all wish for personalised care that accounts for our
underlying genotype, phenotype and environment. For
GDM, we are beginning to understand how and when to
identify and monitor those at greatest risk and to inter-
vene appropriately. We should now aspire to remove the
need for treatment escalation while ensuring that every
patient gets the right treatment from the moment of
diagnosis and attains an optimal pregnancy outcome. The
need for such a personalised approach is particularly
pressing in GDM: in resource-limited health care systems
it is mandatory that we concentrate testing and resources
where we can demonstrate that the most benefit will
occur. An individualised approach to screening, treatment
and monitoring can be the only way ahead.
Abbreviations
ADA: American Diabetes Association; AMPK: Adenosine monophosphate-
activated protein kinase; BMI: Body mass index; FIGO: International
Federation of Gynecology and Obstetrics; GDM: Gestational diabetes mellitus;
HAPO: Hyperglycemia and Adverse Pregnancy Outcomes Study;
IADPSG: International Association of Diabetes and Pregnancy Study Groups;
PCOS: Polycystic ovary syndrome; RCT: Randomized controlled trial;
SMBG: Self-monitored blood glucose; T2DM: Type 2 diabetes mellitus
Acknowledgements
Not applicable.
Funding
Not applicable.
Availability of data and materials
Not applicable.
Authors’ contributions
RSL and SMN were involved in the original conception of the article and all
three authors in writing and reviewing the final manuscript. All authors read
and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
RSL has taken part in advisory boards and as a speaker for Novo Nordisk Ltd
and Eli Lilly. SMN has participated in advisory boards and as a speaker and
has received research support from Roche Diagnostics.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Institute of Cardiovascular & Medical Sciences, BHF Glasgow Cardiovascular
Research Centre, University of Glasgow, University Place, Glasgow G12 8TA,
UK. 2School of Medicine, University of Glasgow, Glasgow Royal Infirmary,
Glasgow G31 2ER, UK.
Received: 20 April 2017 Accepted: 9 August 2017
References
1. Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR,
et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med.
2008;358:1991–2002.
2. Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, et
al. International association of diabetes and pregnancy study groups
recommendations on the diagnosis and classification of hyperglycemia in
pregnancy. Diabetes Care. 2010;33:676–82.
3. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Effect of
treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J
Med. 2005;352:2477–86.
Lindsay et al. BMC Medicine  (2017) 15:163 Page 5 of 7
4. Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, et al. A
multicenter, randomized trial of treatment for mild gestational diabetes. N Engl
J Med. 2009;361:1339–48.
5. World Health Organization. Diagnostic criteria and classification of
hyperglycaemia first detected in pregnancy: a World Health Organization
Guideline. Diabetes Res Clin Pract. 2014;103:341–63.
6. Hod M, Kapur A, Sacks DA, Hadar E, Agarwal M, Di Renzo GC, et al. The
International Federation of Gynecology and Obstetrics (FIGO) initiative on
gestational diabetes mellitus: a pragmatic guide for diagnosis, management,
and care. Int J Gynaecol Obstet. 2015;131 Suppl 3:S173–211.
7. Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 137:
Gestational diabetes mellitus. Obstet Gynecol. 2013;122(2 Pt 1):406–16.
8. National Institute for Health and Care Excellence. Diabetes in pregnancy:
management of diabetes and its complications from preconception to the
postnatal period. https://www.nice.org.uk/guidance/ng3. Accessed 1 Aug 2017.
9. Farrar D, Simmonds M, Bryant M, Sheldon TA, Tuffnell D, Golder S, et al.
Hyperglycaemia and risk of adverse perinatal outcomes: systematic review
and meta-analysis. BMJ. 2016;354:i4694.
10. Catalano PM, McIntyre HD, Cruickshank JK, McCance DR, Dyer AR, Metzger
BE, et al. The hyperglycemia and adverse pregnancy outcome study:
associations of GDM and obesity with pregnancy outcomes. Diabetes Care.
2012;35:780–6.
11. American Congress of Obstetricians and Gynecologists. ACOG Committee
Opinion No. 650: physical activity and exercise during pregnancy and the
postpartum period. Obstet Gynecol. 2015;126:e135–142.
12. Poston L, Bell R, Croker H, Flynn AC, Godfrey KM, Goff L, et al. Effect
of a behavioural intervention in obese pregnant women (the UPBEAT
study): a multicentre, randomised controlled trial. Lancet Diabetes
Endocrinol. 2015;3:767–77.
13. Muktabhant B, Lawrie TA, Lumbiganon P, Laopaiboon M. Diet or exercise, or
both, for preventing excessive weight gain in pregnancy. Cochrane
Database Syst Rev. 2015;6, CD007145.
14. Thangaratinam S, Rogozinska E, Jolly K, Glinkowski S, Roseboom T,
Tomlinson JW, et al. Effects of interventions in pregnancy on maternal
weight and obstetric outcomes: meta-analysis of randomised evidence.
BMJ. 2012;344, e2088.
15. Bain E, Crane M, Tieu J, Han S, Crowther CA, Middleton P. Diet and exercise
interventions for preventing gestational diabetes mellitus. Cochrane
Database Syst Rev. 2015;4, CD010443.
16. Simmons D, Devlieger R, van Assche A, Jans G, Galjaard S, Corcoy R, et al.
Effect of physical activity and/or healthy eating on GDM risk: The DALI
Lifestyle Study. J Clin Endocrinol Metab. 2017;102:903–13.
17. Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R, Kotecha R, et al.
Metformin versus placebo in obese pregnant women without diabetes
mellitus. N Engl J Med. 2016;374:434–43.
18. Chiswick C, Reynolds RM, Denison F, Drake AJ, Forbes S, Newby DE, et al.
Effect of metformin on maternal and fetal outcomes in obese pregnant
women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Lancet Diabetes Endocrinol. 2015;3:778–86.
19. Walsh JM, McGowan CA, Mahony R, Foley ME, McAuliffe FM. Low glycaemic
index diet in pregnancy to prevent macrosomia (ROLO study): randomised
control trial. BMJ. 2012;345, e5605.
20. Koivusalo SB, Rono K, Klemetti MM, Roine RP, Lindstrom J, Erkkola M, et al.
Gestational diabetes mellitus can be prevented by lifestyle intervention: The
Finnish Gestational Diabetes Prevention Study (RADIEL): a randomized
controlled trial. Diabetes Care. 2016;39:24–30.
21. Walsh JM, Mahony RM, Canty G, Foley ME, McAuliffe FM. Identification of
those most likely to benefit from a low-glycaemic index dietary intervention
in pregnancy. Br J Nutr. 2014;112:583–9.
22. Karamanos B, Thanopoulou A, Anastasiou E, Assaad-Khalil S, Albache N,
Bachaoui M, et al. Relation of the Mediterranean diet with the incidence of
gestational diabetes. Eur J Clin Nutr. 2014;68:8–13.
23. Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The many faces of
diabetes: a disease with increasing heterogeneity. Lancet. 2014;383:1084–94.
24. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R.
Reversal of type 2 diabetes: normalisation of beta cell function in
association with decreased pancreas and liver triacylglycerol. Diabetologia.
2011;54:2506–14.
25. Hodson K, Dalla Man C, Smith FE, Barnes A, McParlin C, Cobelli C, et al. Liver
triacylglycerol content and gestational diabetes: effects of moderate energy
restriction. Diabetologia. 2017;60:306–13.
26. Ryan EA. Diagnosing gestational diabetes. Diabetologia. 2011;54:480–6.
27. Waters TP, Dyer AR, Scholtens DM, Dooley SL, Herer E, Lowe LP, et al.
Maternal and neonatal morbidity for women who would beadded to the
diagnosis of GDM using IADPSG criteria: a secondary analysis of the
Hyperglycemia and Adverse Pregnancy Outcome Study. Diabetes Care.
2016;39:2204–10.
28. White SL, Lawlor DA, Briley AL, Godfrey KM, Nelson SM, Oteng-Ntim E, et al.
Early antenatal prediction of gestational diabetes in obese women:
development of prediction tools for targeted intervention. PLoS One.
2016;11, e0167846.
29. Iliodromiti S, Sassarini J, Kelsey TW, Lindsay RS, Sattar N, Nelson SM.
Accuracy of circulating adiponectin for predicting gestational diabetes: a
systematic review and meta-analysis. Diabetologia. 2016;59:692–9.
30. Smith GC. Researching new methods of screening for adverse pregnancy
outcome: lessons from pre-eclampsia. PLoS Med. 2012;9, e1001274.
31. Sovio U, Murphy HR, Smith GC. Accelerated fetal growth prior to diagnosis
of gestational diabetes mellitus: a prospective cohort study of nulliparous
women. Diabetes Care. 2016;39:982–7.
32. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of
glyburide and insulin in women with gestational diabetes mellitus. N Engl J
Med. 2000;343:1134–8.
33. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus
insulin for the treatment of gestational diabetes. N Engl J Med.
2008;358(19):2003–15.
34. Moore TR. Glyburide for the treatment of gestational diabetes. A critical
appraisal. Diabetes Care. 2007;30 Suppl 2:S209–213.
35. Dujic T, Zhou K, Yee SW, van Leeuwen N, de Keyser CE, Javorsky M, et al.
Variants in pharmacokinetic transporters and glycemic response to
metformin: a Metgen meta-analysis. Clin Pharmacol Ther. 2017;101:763–72.
36. Barnes RA, Wong T, Ross GP, Jalaludin BB, Wong VW, Smart CE, et al. A
novel validated model for the prediction of insulin therapy initiation and
adverse perinatal outcomes in women with gestational diabetes mellitus.
Diabetologia. 2016;59:2331–8.
37. Bryson CL, Ioannou GN, Rulyak SJ, Critchlow C. Association between
gestational diabetes and pregnancy-induced hypertension. Am J Epidemiol.
2003;158:1148–53.
38. Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, et al. Low-
dose aspirin to prevent preeclampsia in women at high risk. National
Institute of Child Health and Human Development Network of Maternal-
Fetal Medicine Units. N Engl J Med. 1998;338:701–5.
39. Balsells M, Garcia-Patterson A, Sola I, Roque M, Gich I, Corcoy R.
Glibenclamide, metformin, and insulin for the treatment of gestational
diabetes: a systematic review and meta-analysis. BMJ. 2015;350:h102.
40. Butalia S, Gutierrez L, Lodha A, Aitken E, Zakariasen A, Donovan L.
Short- and long-term outcomes of metformin compared with insulin
alone in pregnancy: a systematic review and meta-analysis. Diabet Med.
2017;34:27–36.
41. Elliott BD, Langer O, Schenker S, Johnson RF. Insignificant transfer of
glyburide occurs across the human placenta. Am J Obstet Gynecol. 1991;
165:807–12.
42. Schwartz RA, Rosenn B, Aleksa K, Koren G. Glyburide transport across the
human placenta. Obstet Gynecol. 2015;125:583–8.
43. American Diabetes Association. Management of diabetes in pregnancy.
Diabetes Care. 2017;40 Suppl 1:S114–9.
44. Lee HY, Wei D, Loeken MR. Lack of metformin effect on mouse embryo
AMPK activity: implications for metformin treatment during pregnancy.
Diabetes Metab Res Rev. 2014;30:23–30.
45. Cassina M, Dona M, Di Gianantonio E, Litta P, Clementi M. First-trimester
exposure to metformin and risk of birth defects: a systematic review and
meta-analysis. Hum Reprod Update. 2014;20:656–69.
46. Rowan JA, Rush EC, Obolonkin V, Battin M, Wouldes T, Hague WM.
Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body
composition at 2 years of age. Diabetes Care. 2011;34:2279–84.
47. Battin MR, Obolonkin V, Rush E, Hague W, Coat S, Rowan J. Blood pressure
measurement at two years in offspring of women randomized to a trial of
metformin for GDM: follow up data from the MiG trial. BMC Pediatr.
2015;15:54.
48. Ijas H, Vaarasmaki M, Saarela T, Keravuo R, Raudaskoski T. A follow-up of a
randomised study of metformin and insulin in gestational diabetes mellitus:
growth and development of the children at the age of 18 months. BJOG.
2015;122:994–1000.
Lindsay et al. BMC Medicine  (2017) 15:163 Page 6 of 7
49. de Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, Evans AT.
Postprandial versus preprandial blood glucose monitoring in women with
gestational diabetes mellitus requiring insulin therapy. N Engl J Med. 1995;
333:1237–41.
50. Bricker L, Medley N, Pratt JJ. Routine ultrasound in late pregnancy (after
24 weeks' gestation). Cochrane Database Syst Rev. 2015;6, CD001451.
51. Sovio U, White IR, Dacey A, Pasupathy D, Smith GC. Screening for fetal
growth restriction with universal third trimester ultrasonography in
nulliparous women in the Pregnancy Outcome Prediction (POP) study:
a prospective cohort study. Lancet. 2015;386:2089–97.
52. Boulvain M, Senat MV, Perrotin F, Winer N, Beucher G, Subtil D, et al.
Induction of labour versus expectant management for large-for-date
fetuses: a randomised controlled trial. Lancet. 2015;385:2600–5.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Lindsay et al. BMC Medicine  (2017) 15:163 Page 7 of 7
